Abstract
Radiohalogens, including fluorine-18 (F-18) and radioiodine (I-123, I-124, and I-131), have been utilized widely for both diagnostic imaging and targeted radionuclide therapy owing to their favorable nuclear properties, well-established radiochemistry, and broad applicability to biomolecules. Among the diverse radionuclides utilized in this field, the production of astatine-211, a promising alpha-emitting radiohalogen, has expanded globally, stimulating a growing interest in theranostic applications that leverage the unique properties of radiohalogens. This review article provides an overview of radiohalogens in nuclear medicine, discussing their current status and future prospects in theranostic radiopharmaceuticals.